Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized CD25 mAb + Glucocorticoid for First-line aGVHD
NCT06473909Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of daclizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
daclizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06473909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473909.